Clidacor Capsule

Clindamycin.

Each capsule contains: Clindamycin HCl equivalent to Clindamycin 300 mg.

Pharmacology: Clindamycin is Lincomycin antibiotic with primary bacteriostatic action against gram positive aerobic and anaerobic bacteria.
Clindamycin exert it antimicrobial effect by inhibiting protein synthesis with binding to the bacterial 50-S ribosomal subunit.

For treatment of serious infections caused by susceptible anaerobic gram-positive bacteria due to susceptible strains of Streptococcus, Pneumococcus, and Staphylococcus in: Respiratory tract infections: empyema, pneumonitis anaerobic, and lung abscess; Serious skin and skin structure infections; Septicaemia; Intra-abdominal infections such as peritonitis and intra-abdominal abscess; Infections of the female pelvis and genital track such as endometritis, pelvic cellulites, and post-surgical vaginal cuff infection; Bone infections.

Adults: Serious infections: 150 mg-300 mg every six hours.
Severe infections: 300 mg-450 mg every six hours.
Children: Serious infections: 3-6 mg/kg every 6 hours depending on the severity of the infection.
If diarrhea occurs as long as medications, the drugs should be discontinued.
To avoid the possibility of oesophageal irritation, capsules should be taken with a full glass of water. In cases of β-haemolytic streptococcal infections, treatment should continue for at least 10 days.

No special medications. If allergic reactions occur, the usual agents (Corticosteroids, Adrenalin, and Antihistamine) should be available for emergency treatment.

For patients who develop hypersensitivity to Clindamycin.

Clindamycin should be reserved for serious infections.
Clindamycin it should not be used in patients with upper respiratory tract infections.
Used with caution individuals with a history of gastrointestinal disease, particularly colitis.
Patients with hepatic or renal impairment dosage may be decreases because in this patients serum half-life of Clindamycin may be prolonged.
Prescribed with caution in elderly patients, they should be monitored for change in bowel frequency because in elderly patients with severe infections sensitive to diarrhea.
Prescribed with caution in atopic individuals.
The use of Clindamycin occasionally results in overgrowth of non-susceptible organism particularly yeasts. Should superinfections occur, appropriate measure should be taken as indicated by the clinical situation.
In surgical procedures should be performed in conjunction with antibiotic therapy.
During prolonged therapy, periodic liver and kidney function tests and blood counts should be monitored during high-dose therapy.
Since Clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.
Clindamycin is excreted into breast milk, because of the potential for adverse reactions in nursing neonatus from Clindamycin, a decision should be made whether to continue or discontinue nursing, taking into account the importance of the drug.
In patients with severe renal disease accompanied by severe metabolic disorders, medication doses should be given with caution, and serum Clindamycin levels should be monitored during high-dose treatment.
Giving the newborn to do proper observation of organ function. For injection containing Benzyl alcohol additives can cause Gasping Syndrome in premature infants.

Gastrointestinal: Colitis association with antibiotics, abdominal pain, nausea, vomiting, diarrhea, and metallic taste in the mouth or bad taste after administration of high doses IV of Clindamycin HCl.
Hypersensitivity reactions: Maculopapular rash and urticaria, generalized mild to moderate morbili form-like skin rashes, Stevens-Johnson Syndrome, and anaphylactoid.
Liver: Jaundice and abnormalities in liver functions tests.
Renal: Renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria.
Haemopoietic: Neutropenia (leucopenia) and eosinophilia, rare cases of agranulocytosis and thrombocytopenia.
Musculoskeletal: Rare instances of polyarthritis have been reported.
Skin and mucous membranes: pruritis, vaginitis, and rare instances of exfoliative and vesiculobullous dermatitis.
Local reaction: pain, induration, abscess after IV infusion.
Cardiovascular: rare cardiopulmonary arrest and hypotension.

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.
In vitro antagonism has been demonstrated between Clindamycin and Erythromycin, because it is have clinically significant possibility, it may be advisable to separate the time of administration of each drug.

Store below 30°C.

Other Antibiotics

J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.

G